Peptides for detox FAQ

Elevated ALT (alanine aminotransferase) or AST (aspartate aminotransferase) indicates hepatocyte damage, not necessarily impaired detoxification capacity, but the two often overlap. Before adding peptides for detox, identify the cause. Nonalcoholic fatty liver disease, alcohol use, viral hepatitis, or medication-induced hepatotoxicity all require different interventions. If the cause is oxidative stress or metabolic overload, NAC and silymarin (milk thistle) have the strongest evidence for reducing liver enzyme elevations. A 2020 meta-analysis in Hepatology found NAC reduced ALT by 15–25 IU/L in NAFLD patients over 12 weeks. Peptides like Thymalin or MOTS-c lack direct evidence for improving liver enzyme markers and should be considered experimental adjuncts, not primary interventions.

Fasting activates autophagy through mTOR suppression and AMPK activation. Mechanisms that overlap with peptides like MOTS-c but don't require exogenous administration. Adding peptides during fasting risks counteracting the fasting state: amino acid-containing peptides (anything longer than a tripeptide) trigger an insulin response and suppress autophagy via mTOR reactivation. If the goal is glutathione support during fasting, NAC is appropriate because it's an amino acid derivative, not a peptide chain, and doesn't meaningfully affect mTOR signaling. For mitochondrial support, consider timing MK 677 or similar compounds to feeding windows rather than fasted periods, as their growth hormone-stimulating effects are amplified by nutrient availability.

Prioritise peptides that directly increase intracellular glutathione rather than those with speculative autophagy effects. NAC at 600–1200mg twice daily is the evidence-based starting point. It provides cysteine in a form that bypasses the rate-limiting enzyme in glutathione synthesis. If oral NAC causes gastrointestinal upset (common at doses above 1200mg/day), liposomal glutathione (500–1000mg daily) offers an alternative with improved absorption. Combine with dietary sources of glycine and glutamate (bone broth, collagen peptides) to ensure the other two amino acids aren't limiting factors. Mitochondrial support through CoQ10 (200–400mg ubiquinol form) enhances ATP production and reduces the oxidative load that glutathione must address.

Consult your prescribing physician before adding glutathione precursors during active medication protocols. NAC at high doses can interfere with chemotherapy efficacy by scavenging reactive oxygen species that certain drugs rely on to kill cancer cells. This is a well-documented interaction with cyclophosphamide and doxorubicin. In acetaminophen overdose, IV NAC is the standard of care precisely because it restores glutathione before toxic NAPQI metabolite accumulation causes liver necrosis. But timing and dose are critical, and this is a hospital-administered protocol, not a home regimen.

Verify peptide storage and reconstitution first—temperature excursions above 8°C or improper mixing denature peptide structure without visible changes. If storage was correct, the issue is likely pathway mismatch: you may be using a mitochondrial peptide when glutathione is the bottleneck, or an autophagy trigger when Phase II conjugation is rate-limiting. Run baseline labs (serum glutathione:GSSG ratio, urinary 8-OHdG, hepatic transaminases) to identify which detox pathway is impaired, then select peptides targeting that mechanism specifically.

This is synergistic—fasting elevates AMPK and suppresses mTOR, both of which enhance autophagy and mitochondrial efficiency. Administer autophagy-inducing peptides (selank, Dihexa) at least 12–16 hours into the fast when autophagic flux is already elevated. Mitochondrial peptides (epithalon, MOTS-c) work best during the fed window when ATP demand is high. Do NOT use growth-promoting peptides like MK 677 during fasting—they activate mTOR and suppress autophagy, counteracting the detox benefit.

This suggests mobilization of stored toxins faster than conjugation and elimination pathways can handle—common when using autophagy-inducing peptides without adequate glutathione support. The cellular cleanup releases oxidized proteins and lipid peroxides into circulation before Phase II enzymes conjugate them. Solution: add a glutathione-modulating peptide like thymalin or BPC-157, increase hydration to support renal clearance, and consider splitting doses to slow mobilization rate. Symptoms typically resolve within 5–7 days as conjugation capacity catches up.

Use liposomal glutathione or switch to NAC and glycine instead. Standard oral glutathione is degraded by intestinal peptidases into its component amino acids (cysteine, glycine, glutamate) before systemic absorption. Bioavailability is less than 5%, meaning the liver must reassemble the tripeptide from scratch. Liposomal encapsulation protects the peptide during digestion and increases uptake to 25–30%, but even then, precursor supply (NAC 600mg + glycine 3g twice daily) produces higher hepatic GSH levels in comparative studies because it bypasses the degradation step entirely.

Start at 300mg once daily and titrate upward over 2 weeks. NAC's sulfurous metabolites can irritate gastric mucosa in 15–20% of users, particularly at doses above 1200mg daily. Taking it with food, splitting the dose into three administrations instead of two, or switching to a sustained-release formulation reduces GI side effects without compromising efficacy. If nausea persists, glycine monotherapy (5g twice daily) restores hepatic glutathione by 20–25% over 12 weeks without the sulfur-related irritation.